Summary of head‐to‐head comparisons of patient risk classifications by the 21‐gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer

Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21‐gene assay results have shown that chemotherapy may be safel...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 145; no. 4; pp. 882 - 893
Main Authors Varga, Zsuzsanna, Sinn, Peter, Seidman, Andrew D.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 15.08.2019
Wiley Subscription Services, Inc
Subjects
Assaying
Breast cancer
Chemotherapy
Health risks
Medical research
multigene tests
risk score comparison
risk score comparison
breast cancer
multigene tests
Online AccessGet full text

Cover

More Information
Summary:Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21‐gene assay results have shown that chemotherapy may be safely omitted in EBC patents with low Recurrence Score (RS) results (RS < 18). Because of its extensive validation and wide clinical use, the RS assay is a common comparator in head‐to‐head studies with other assays. Published/presented studies of the RS assay performed on the same tumor samples with Breast Cancer Index (BCI), EndoPredict (EP) or EP+ clinical features (EPclin), MammaPrint (MMP) and/or Prosigna (ROR) assays were reviewed. Study findings were summarized descriptively.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.32139